Mark Schoenebaum was a brilliant and successful Wall Street research analyst who fundamentally changed the way sell-siders cover biotech stocks. More importantly, Mark was a remarkably nice guy. Wall Street is not known for warm and fuzzy people, but Mark smashed that mold. He was kind and funny. He was gregarious and uncommonly generous to colleagues, friends, and even strangers.
Most of the biotech investment community first heard about Mark’s death via a gut-wrenching email sent by his friend and former colleague Umer Raffat on Sunday evening.
“We’ve all looked up to him as the very best equity research analyst there has ever been on Wall Street,” Raffat wrote. “But that was only part of who he was: he was an absolute standout individual who touched so many lives, and whose strength of character showed in his sheer humility despite his absolutely unprecedented success.”
About the Author Reprints
Adam, your article was perfect. I knew Mark for >15 years so I feel qualified to opine. And more importantly, his legacy deserves this remembrance. Bravo!!!
Adam – beautifully written. Mark will be missed. (Mary – our hearts are with you and your family.)
Adam, your eloquent piece about my beloved son, Mark, will be in my memory forever. You nailed it! Im so glad that “Wall Streeters” knew the real Mark. Thank you
Mary — I am so sorry for your loss. I hope this piece gives you some small comfort in knowing how much Mark was admired and respected by the biotech community. It was an honor to know him and call him a friend. He is truly missed.
Mark was an amazing guy and research analyst. When I started my career he always made himself available to talk and share his insights and learnings. Biotech lost a standup guy. He will be missed by many of us.
Ditto! Adam, you beautifully captured what made Mark so incredible to so many people. Thank you. He was an extraordinary analyst, teacher and person and knew just how to make analyzing biotech data fun.
As far as I can tell, Mark single-handedly redefined what it meant to be a sell-side analyst. All that stuff folks do routinely today, he created. I’m shocked and saddened.
Beautiful guy. Will be sadly missed.
Thanks Adam for expressing what so many of us are feeling today. Mark was one of a kind (often imitated now). It did not take long after I started covering biotech in 2002 to figure out that Mark was a first call go-to guy for so many complicated stories. Quick to respond, generous with his time and very funny. A tough combo to beat. Gone far too soon.
Very nicely done, Adam.